Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data Cellectis S.A. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2017
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
44.8
25.2
12.7
15.2
51.1
30.3
19.2
0.76
41.5
72.9
Cost of revenue
2.62
2.74
11.4
1.95
1.84
1.77
0.74
0
0
Gross profit
22.6
9.99
3.8
49.1
28.5
17.4
0.02
41.5
72.9
Research and development
78.5
79.2
76.6
92
77
118
97.5
87.6
90.5
93.5
Selling, general and administrative
43.4
44.8
47.2
43
22.5
22.9
17.5
16.8
19.1
19.8
Operating income
-67.3
-92.7
-105
-124
-42.3
-103
-89.7
-97.3
-59.6
-33.1
Interest expense
7.1
18.3
3.81
3.63
16.1
6.49
17.8
40.6
21.6
51.1
Interest income
7.15
7.26
20.6
12
4.85
13.2
8.88
21.5
44.4
16.1
Pre-tax income
-67.3
-104
-88.3
-115
-53.6
-96.7
-98.6
-116
-36.8
-68
Income tax
0
0
0
0
0
0
0.09
0.37
0
-0.42
Income from continuing operations
-67.3
-104
-88.3
-115
-53.6
-96.7
-98.7
-117
-36.8
-67.6
Net income to minority interests
-4.32
-9.64
-13.1
-16.4
-10.9
-7.89
-7.38
0
0
Net income
-67.3
-99.4
-78.7
-102
-81.1
-114
-106
-101
-36.8
-67.6
EBITDA
-65.1
-89.3
-103
-117
-32.5
-95.9
EPS, basic
-1.91
-2.78
-1.93
-2.41
-1.91
-2.55
-2.33
-1.77
-0.41
-0.67
EPS, diluted
-1.91
-2.78
-1.93
-2.41
-1.91
-2.55
-2.33
-1.77
-0.41
-0.67
Balance sheet
FY2017
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
255
256
452
341
241
186
93.2
137
143
61.5
Inventory
0.12
0.25
0.28
2.9
1.6
0
0
Total current assets
312
323
488
392
315
225
122
Property, plant and equipment
16.9
7.23
8.73
23.7
71.7
78.8
63.6
54.7
45.9
38.8
Lease right-of-use assets
45.6
73.8
69.4
44.3
38.1
30
23.7
Intangible assets
1.12
0.54
Total assets
331
333
501
467
469
382
261
334
384
325
Total current liabilities
56.2
45.5
46.9
62.6
52
49.3
48.1
155
166
146
Lease liabilities
1.02
46.5
75.8
71.5
49.4
42.9
34.2
27.7
Total liabilities
58.4
48.9
50.6
112
161
146
135
250
253
249
Paid-in capital
568
614
829
843
872
935
583
523
494
437
Retained earnings
-210
-254
-327
-406
-506
Shareholders' equity
273
265
409
315
284
221
118
84.7
131
75.9
Minority interests
1.88
19.1
41
40.3
25.1
15.2
7.97
0
Total equity
273
284
450
355
309
236
126
84.7
131
75.9
Total liabilities and equity
331
333
501
467
469
382
261
334
384
325
Cash flow statement
FY2017
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-67.3
-104
-88.3
-115
-97.5
-125
-114
-108
-36.8
-67.6
Depreciation and amortization
2.21
3.37
2.38
6.88
9.82
7.58
Cash from operations
-32.7
-52.3
-68.1
-69.1
-80.3
-105
-87.4
-24.7
23
-39.4
Capital expenditures
-13.7
-2.38
-4.72
-12.9
-44.1
-18.5
-2.43
-1.07
-2.58
-2.36
Cash from investing
-53.1
1.78
35.6
-35.9
-54.3
7.28
-2.76
-15.5
-103
-29.5
Debt issued
0
5.75
29.7
23.2
0
Debt repaid
-0.09
-0.04
-0.13
0
0
-1.34
-5.11
-5
-5.38
Stock issued
0.71
2.93
186
0
44.6
-0.57
Cash from financing
0.49
41.3
236
-3.86
27.3
47.5
1.15
82.9
89.1
-16.8
Exchange rate effect
-2.18
11.1
-8.86
-2.1
7.91
-5.75
-3.36
0.88
-2.75
3.93
Net change in cash
-85.4
-9.28
204
-109
-107
-49.8
-89.1
42.6
9.3
-85.6
Free cash flow
-46.4
-54.7
-72.9
-82.1
-124
-123
-89.9
-25.8
20.4
-41.8
Income taxes paid
0.01
Key metrics
Worked out from the statements above. Latest values use fiscal 2025. Valuation uses the share price of $1.47 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Gross margin
100.0%
Gross profit / revenue.
Operating margin
-45.3%
Operating income / revenue.
Pre-tax margin
-93.2%
Pre-tax income / revenue.
Net margin
-92.7%
Net income / revenue.
FCF margin
-57.2%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-54.0%
Cash from operations / revenue.
Return on equity (ROE)
-65.3%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-19.1%
Net income / average total assets.
Return on invested capital (ROIC)
-2,431.0%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue
128.2%
Research and development expense / revenue.
SG&A / revenue
27.1%
Selling, general and administrative expense / revenue.
Capex / revenue
3.2%
Capital expenditures / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
75.8%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
56.1%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
7.4%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Gross profit growth, 1y
75.8%
Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y
61.2%
Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit CAGR, 5y
8.2%
Compound annual growth of gross profit over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Operating cash flow growth, 1y
-271.4%
Operating cash flow vs the same period a year earlier. Only from a positive base.
Free cash flow growth, 1y
-304.7%
Free cash flow vs the same period a year earlier. Only from a positive base.
Book value growth, 1y
-42.1%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
-13.7%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
-23.2%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
-15.3%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
7.5%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
-7.1%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Balance sheet health
Metric
Value
How it is calculated
Quick ratio
0.42x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.42x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
EPS, basic
-$0.67
Net income per basic share, as reported (split-adjusted).
Valuation
Metric
Value
How it is calculated
Market cap
$147.8M
Share price x shares outstanding.
Enterprise value
$86.2M
Market cap + total debt - cash - short-term investments.
P/S
2.03x
Market cap / revenue.
P/B
1.95x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
1.96x
Market cap / tangible book value, when positive.
EV/Sales
1.18x
Enterprise value / revenue.
FCF yield
-28.3%
Free cash flow / market cap.
Earnings yield
-45.7%
Net income / market cap (the inverse of P/E).
What was Cellectis S.A.'s revenue in fiscal 2025?
Cellectis S.A. reported revenue of $72.9M for fiscal 2025, 75.8% higher than the year before.
Was Cellectis S.A. profitable in fiscal 2025?
No. It reported a net loss of $67.6M.
How much free cash flow did Cellectis S.A. generate in fiscal 2025?
Cash from operations of $39.4M minus capital expenditures of $2.4M left free cash flow of -$41.8M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.